Here's Why Teva Shares are Trending Higher Today - TipRanks.com
Teva Seeks New CFO as It Faces High Debt Levels, Opioid Litigation - WSJ
Teva Stock: Teva Guides To Its First Year Of Growth Since 2017, But There's A Caveat | Investor's Business Daily
The Teva-Allergan deal shows why pharma mergers are booming | Fortune
Teva Pharmaceuticals will pay $420 million in a federal case
Why the Teva Pharmaceuticals Stock Rebound May Be Real | InvestorPlace
Teva Pharmaceutical: Investment Opportunity During Fed Rate Hike (NYSE:TEVA) | Seeking Alpha
Five Considerations After Teva Pharmaceuticals' Q3 Report (NYSE:TEVA) | Seeking Alpha
NuPathe acquired by Teva for $144M - Technical.ly
6 Reasons I've Been Aggressively Buying Teva Pharmaceutical Industries | The Motley Fool
Teva Pharmaceutical to Nominate Four New Directors - WSJ
Analysis: Teva Pharmaceuticals is bogged down by legal issues, fails to kick-start growth | Ctech
Investors question green tint of Teva's $5bn sustainability bond | Financial Times
Suffering from missteps, drugmaker Teva struggles to heal own ills | The Times of Israel
Teva Pharmaceutical Industries — 9 Portfolio companies, 10 Investments, Team — Unicorn Nest
Capital Research Global Investors increases ownership in TEVJF / Teva Pharmaceutical Industries Ltd.
Teva Bonds: 8.8% Yield To Maturity Understates Upside | Nasdaq
Jewish Values Investors JLens Target Israeli Company
Teva dispenses $2.6 million to resolve ERISA claims | Pensions & Investments
Teva Selling $3.5 Billion of Junk Bonds to Refinance Debt - Bloomberg
Teva Investor Relations by Teva Pharmaceuticals USA, Inc.
Teva ponies up $420M to settle with investors who said company hid price-fixing scheme | Fierce Pharma
Teva Pharmaceutical Stock Could Double | Barron's
